52-Week Performance Chart

From time to time, BNY may pay a rebate to brokers that deposit shares with BNY for the issuance of unsponsored depositary receipts (DRs) or global depositary notes. BNY assumes no obligation or responsibility, and expressly disclaims any liability arising out of, or relating to, such rebates, including without limitation whether the rebate or any portion of it is passed on to the beneficial holders by the brokers.
Unsponsored DRs may be issued by multiple depositary banks servicing a particular DR program. Consequently, as a result of Depository Trust & Clearing Corporation (“DTCC”) practice, the actual cash distribution fees charged may differ from the BNY fees detailed in the fee schedule as fees will be charged in accordance with the fee schedule of the depositary bank that is considered to be the “First Filer”. The fees to be charged for any particular unsponsored cash distribution will be disclosed on the event announcement published by the “First Filer”. BNY takes no responsibility for the level of fees charged by any other depositary bank. The “First Filer” is the depositary bank that filed the first Form F-6 for a program with the U.S. Securities and Exchange Commission (“SEC”). In the event the actual “First Filer” does not have DRs outstanding for a program, the next depositary bank who filed a
Form F-6 with the SEC and has DRs outstanding will be deemed to be the First Filer for these purposes.

DR Details

DR Symbol	SSMXY
CUSIP	87184P109
DR Venue	OTC
DR ISIN	US87184P1093
Ratio DR:ORD	1:1
First Filer	BK
Underlying ISIN	JP3351100007
Underlying SEDOL	6883807
Country	Japan
Effective Date	Apr 13, 2011
Depositary	BK, CIT, DB, JPMC (Unsponsored)
Industry	HealthCareEquip.&Ser

Sysmex is mainly engaged in the development, manufacture, and sale of diagnostic equipment and reagents. The Company's principal products include clinical analyzers and systems, particle counters/analyzers, digital imaging devices, data management systems, software and other diagnostic instruments, as well as vitro diagnostic reagents in the filed of hematology, hemostasis, urinalysis, immunochemistry and flow cyrometry analysis. The Company also provides contract analysis and protein production services, as well as training programs and scientific seminars. The Company operates its business activities in Japan, Americas, EMEA (Europe, the Middle East and Africa), China, and Asia Pacific regions.

Data provided by Mergent, Inc.

Fee Type in US Dollar per ADS	Deposit Agreement
Annual Depositary Service	up to $0.1000
Cancellation	up to $0.1000
Cash Distribution	up to $0.1000
Issuance	up to $0.1000
Registrar Inspection	up to $0.0000
Cash Distribution(Other)	up to $0.1000
Rights - Issuance	up to $0.1000
Stock Dividend	up to $0.1000
Transfer	up to $0.0000
Cable Fee per Cancellation	$17.5000

Monthly Trading Summary

Month	Month End DR Close Price	DR Trading Volume	Avg Day DR Trading Volume
May.25	16.76	1,755,716	83,606
Apr.25	18.46	1,505,268	71,679
Mar.25	18.97	1,129,546	53,788

Depositary Receipts Foreign Exchange Pricing Disclosure